Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.75 |
| ▸ | EGFR | P00533 | 16/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.75 |
| ▸ | FLT1 | P17948 | 9/20 | 0.75 |
| ▸ | FLT4 | P35916 | 9/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.75 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.75 |
| ▸ | TEK | Q02763 | 2/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.75 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.75 |
| ▸ | CIT | O14578 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781194 | 0.95 | KDR (0.67) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2055590 | 0.93 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13617552 | 0.91 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2136853 | 0.91 | KDR (0.74) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3152430 | 0.90 | KDR (0.80) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13163378 | 0.90 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL27382243 | 0.90 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13617346 | 0.89 | KDR (0.61) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL20341372 | 0.89 | KDR (0.74) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL1781457 | 0.88 | KDR (0.58) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | claimed |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024025991-A1 | METHODS FOR DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION | THE METHODIST HOSPITAL SYSTEM (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2007036713-A2 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1446124-B1 | COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142316-A1 | Combination therapy | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1534287-A1 | COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| WO-2004014383-A1 | COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 207/4885FGFR1 154/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885FGFR1 196/4885 |
| US-20220033377-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885FGFR1 2445/4885 |
| US-20240150317-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885FGFR1 2445/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885FGFR1 135/4885 |
| US-20190263782-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885FGFR1 2445/4885 |
| US-20060142316-A1 | Combination therapy | VEGFA, FLT4, FLT1 | KDR 24/4885EGFR 1367/4885FGFR1 943/4885 |
| US-20050222183-A1 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | FLT4, KDR, TEK | KDR 2/4885EGFR 7/4885FGFR1 186/4885 |
| US-20050043395-A1 | Combination therapy comprising zd6474 and a taxane | ZYX, VEGFA, TEK | KDR 4/4885EGFR 192/4885FGFR1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.